Jefferies puts NPS at buy

NPS Pharmaceuticals was reiterated at buy by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies said it is encouraged by fourth-quarter 2005 Forteo sales of $118 million that suggests the anabolic market is growing. NPS reported non-GAAP fourth-quarter 2005 net loss of $0.96 per share, compared with the analyst's estimate of $0.93 and the Street consensus of $1.01. Shares of the Salt Lake City pharmaceutical company were down 2 cents, or 0.14%, at $13.92 on volume of 549,601 shares versus the three-month running average of 549,416 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.